An approved dual agonist versus an investigational triple agonist.
Bottom line: Tirzepatide is available in named FDA-approved products. Retatrutide is still investigational. Sponsor-reported Phase 3 topline results do not make it approved or eligible for compounding. [1–6]
| Tirzepatide | Retatrutide | |
|---|---|---|
| Status | FDA-approved as Mounjaro and Zepbound for labeled uses. [2] | Investigational; FDA says it cannot be compounded under federal law. [4,6] |
| Comparative efficacy | No completed head-to-head tirzepatide-versus-retatrutide trial establishes superiority. | TRIUMPH-1 compared retatrutide with placebo, not tirzepatide. [4,5] |
| Patient instructions | Use the exact label and prescription. [2] | No consumer dose, switch, reconstitution or routine schedule is established. |
summary: Tirzepatide is available in named FDA-approved products. Retatrutide is still investigational. Sponsor-reported Phase 3 topline results do not make it approved or eligible for compounding. [1–6]
trials: []
No. It compares evidence and status. Use the exact approved label and prescriber plan, or a registered clinical-trial protocol if you are enrolled.
Educational evidence summary. Approved products, patient-specific compounded preparations, clinical-trial products, and research-market products are not interchangeable categories.
